Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,418 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,888 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,375)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE(GRALE) |
| recruiting |
| Phase 1 |
| 136 |
| Baylor College of MedicineOTHER |
| 1 |
| Mar 2, 2026 |
| clinicaltrials |
| NCT07169500 | Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07441954 | Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma(GP-1) | not yet recruiting | Phase 1 / Phase 2 | 53 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 2, 2026 | clinicaltrials |
| NCT03434769 | AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma | active not recruiting | Phase 1 | 31 | Benjamin TomlinsonOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04764942 | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | active not recruiting | Phase 1 / Phase 2 | 39 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06235229 | A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma(DURGA-3) | recruiting | Phase 1 / Phase 2 | 110 | Gracell Biotechnologies (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 68 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | withdrawn | Phase 1 | 0 | Ossium Health, Inc.INDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05371054 | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05432635 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | completed | Phase 1 / Phase 2 | 97 | BeiGeneINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | recruiting | Phase 1 / Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05577000 | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 5 | Thomas Martin, MDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06475235 | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03930953 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | active not recruiting | Phase 1 / Phase 2 | 438 | CelgeneINDUSTRY | 15 | Feb 19, 2026 | clinicaltrials |
| NCT07421856 | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. | not yet recruiting | Phase 1 / Phase 2 | 24 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 0 | Feb 19, 2026 | clinicaltrials |
| NCT03779113 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | terminated | Phase 1 | 69 | HutchmedINDUSTRY | 7 | Feb 18, 2026 | clinicaltrials |
| NCT06863259 | Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL | recruiting | Phase 1 | 28 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03033914 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | active not recruiting | Phase 1 / Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT05350787 | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL | completed | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05391750 | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | active not recruiting | Phase 1 | 7 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05551936 | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 42 | Vaishalee KenkreOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04775745 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | recruiting | Phase 1 | 60 | Newave Pharmaceutical IncINDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT07333261 | Study of BMS-986453 in Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 | 25 | Susan BalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07407010 | BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM(CM336-001) | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT03029338 | CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | completed | Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04067414 | Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma | completed | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04316624 | A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy | completed | Phase 1 | 7 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04322292 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | completed | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04690595 | BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | active not recruiting | Phase 1 | 24 | PeproMene Bio, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07018752 | A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas(PlaTform) | recruiting | Phase 1 / Phase 2 | 49 | The Lymphoma Academic Research OrganisationOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03031730 | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | terminated | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04848064 | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | recruiting | Phase 1 | 12 | John ReneauOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06287528 | A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06939283 | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | active not recruiting | Phase 1 / Phase 2 | 100 | Werewolf Therapeutics, Inc.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07398638 | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study | not yet recruiting | Phase 1 / Phase 2 | 122 | Sun Yat-sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07400744 | A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects | not yet recruiting | Phase 1 | 102 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 10, 2026 | clinicaltrials |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | terminated | Phase 1 / Phase 2 | 200 | CelgeneINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT03581942 | Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | completed | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03938987 | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)(ACIT001/EXC002) | recruiting | Phase 1 / Phase 2 | 63 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04674813 | A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 130 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06705530 | A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders | completed | Phase 1 / Phase 2 | 58 | National Research Center for Hematology, RussiaNETWORK | 1 | Feb 9, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 4, 2026source: clinicaltrials